Company ProfilePremium

Aimco Pesticides Limited

Company Profile Analysis

Ticker: 524288.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Aimco Pesticides Limited - Company showcase

Year Founded & Workforce

1987

Aimco Pesticides Limited logo

Aimco Pesticides Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Aimco Pesticides Limited Overview

Aimco Pesticides is a promoter-controlled Indian micro-cap agrochemical manufacturer that operates a single multi-product plant at Lote Parshuram (Ratnagiri, Maharashtra) with installed capacity of 18,500 MT per annum. Historically an export-led technical-grade producer — it was among the earliest Indian commercializers of chlorpyrifos and triclopyr technical and added bifenthrin in 2017 — the company also sells bulk (B2B) formulations and a growing portfolio of domestic branded formulations through its own distributor network. Roughly half of revenue has come from exports to Australia, the USA, Malaysia, Brazil, Africa and the Gulf. Since FY2022's record year (revenue INR 312 Cr), the business has contracted sharply under Chinese price competition, global channel destocking and the expiry of a large contract-manufacturing agreement; it has posted four consecutive annual losses and net worth has fallen to INR 17.7 Cr. Management is pivoting to branded formulations, new molecules and overseas subsidiaries while its credit standing deteriorates.


What the company does

Aimco Pesticides manufactures, markets and exports crop-protection chemicals across the three principal classes — insecticides, fungicides and herbicides — and to a lesser extent rodenticides and fumigants. It describes itself in exchange filings as a diversified, integrated agrochemical company engaged in manufacturing and trading of agrochemical products, including technical grade pesticides, formulations and a wide range of agrochemical inputs (Annual Report FY2024-25, as summarized by Screener). Its portfolio spans approximately 11 technical-grade active ingredients, 90+ formulations and 300+ branded SKUs (CARE Ratings, Jul 2023).

Business model and revenue streams

Revenue streamDescriptionCustomer typeMargin profile (per management/CARE)
Technicals (manufactured active ingredients)Technical-grade chlorpyrifos (ethyl and methyl), triclopyr, bifenthrin and other molecules, sold in bulk to formulators in India and abroad; also produced under contract manufacturingGlobal and Indian agrochemical companies, overseas registrants/distributors (primarily Australia, USA)Described by CARE as low-margin relative to branded formulations; management has also called technical sales higher-margin than B2B formulations
B2B formulationsBulk formulated products supplied to other companies for re-brandingIndian and overseas agrochemical marketersLowest margin; consciously de-emphasized from FY2021
Branded formulations (B2C)Company-branded formulations sold to farmers through distributors and dealers in IndiaDistributors / retailers / farmersHighest margin; strategic growth focus since FY2024
TradingTraded agrochemical productsMixedSecondary

The company has consistently presented four revenue streams in its investor presentations (Q1FY21, Q3FY21, Q4FY23, Q4FY25 presentations):

The revenue model is entirely product-based (no service, subscription or licensing income of significance). Contract manufacturing — notably a three-year agreement from 1 April 2021 with an unnamed Indian agrochemical major, expected to generate INR 225–250 Cr over its tenure (company press release, March 2021, via AgroPages) — is a product-supply arrangement rather than a fee-for-service model.

Value-chain position

Aimco sits in the middle of the agrochemical value chain: it buys intermediates and raw materials (around half imported, predominantly from China, per CARE Oct-2025), synthesizes active ingredients (technicals), and either sells technicals downstream or formulates them into end-use products. In the domestic branded channel it reaches the farm gate via distributors. It does not undertake proprietary new-active-ingredient discovery at scale; its R&D focus is process chemistry for off-patent (generic) molecules.

Customer types and end-markets

Export customers: formulators and registrants in Australia, USA, Malaysia, Brazil, Africa and Gulf markets; historically ~42–45 export countries (Q3FY21 presentation; CARE Jul-2023). Exports were ~50% of revenue in FY2023 (CARE, Sep 2023).

Domestic B2B customers: Indian agrochemical companies (including the contract-manufacturing counterparty, FY2022–FY2024).

Domestic farmers via distributors: branded formulations sold primarily in West Bengal, Gujarat, Odisha, Andhra Pradesh, Tamil Nadu, Madhya Pradesh and Maharashtra (Q4FY25 earnings presentation). An earlier broker profile cites 285 active distributors (domestic and overseas) — date of that figure not confirmed.

Customer concentration: top ten customers contributed more than 50% of revenue in FY2024 (CARE, Oct 2025).

Independent characterization

Aimco is best understood as a sub-scale, generic-molecule technical producer that tried to migrate up the value chain into domestic brands just as the global generic agrochemical cycle turned down. Its legacy strengths (early-mover process know-how in chlorpyrifos/triclopyr, export registrations, a flexible plant) became liabilities as chlorpyrifos faced regulatory restrictions in major markets and Chinese producers flooded generic markets after 2022. The company's economics are highly exposed to (i) export price realization for a handful of molecules, (ii) Chinese raw-material costs, and (iii) Indian monsoon-driven seasonality in the branded business. With FY2026 revenue of INR 153.9 Cr and negative EBITDA, it lacks the scale to absorb fixed costs, and its balance sheet is now sustained largely by supplier credit (payables of INR 87.3 Cr against equity of INR 17.7 Cr at 31 Mar 2026).

Strategy

Stated strategy themes (paraphrased from filings, calls and CARE summaries)

  1. Mix shift to branded formulations. From FY2024, management planned to focus on branded formulations because technicals are lower-margin relative to brands (CARE, Jun 2024 / Oct 2025). Branded share rose from 22% (FY2022) to 29% (FY2023); brand growth was reported in FY2025.

  2. New molecules less exposed to China. Three new molecules entered production in FY2025, chosen because Chinese players do not supply them at scale; two had been stabilized by mid-2025 with own-brand formulations launched for both (9 Jun 2025 call; CARE).

  3. De-risking raw-material supply. Management aims to reduce reliance on Chinese intermediates in favour of local sources (CARE).

  4. Portfolio adjacencies. Planned entry into plant growth regulators, bio-nutrients and bio-stimulants (Annual Report FY2025 summary).

  5. International subsidiaries. Build-out of Aimco KREPL Australia (2024–25) and recapitalization of Aimco International FZE (Dubai) and Aimco Ecoscience (India).

  6. Research partnerships. University of Melbourne student research project on novel agricultural products (Jun 2026).

  7. Liquidity management. Working-capital release in FY2026, debt repayment (INR 5.4 Cr net), and sale of a non-core residential asset.

Initiative register — last 24 months

DateInitiativeTypeQuantificationStatus
May 2024 – Jun 2025Aimco KREPL Australia set up and capitalizedMarket expansionAUD 10,000 + AUD 30,000Subsidiary active; revenue not disclosed
Dec 2024Additional capital to Aimco International FZEMarket expansionAED 150,000Completed
Dec 2024 – Jan 2025Additional capital to Aimco Ecoscience LtdAdjacency (inferred bio/eco)INR 5 lakhCompleted
Jan–Mar 2025Preferential issueCapital raising2,00,000 shares; INR 2.02 CrAllotted 6 Mar 2025
FY2025Three new molecules commercializedProductNot quantifiedTwo stabilized by Jun 2025
Jun 2025FY2026 revenue targetGuidanceINR 225 CrMissed (actual INR 153.9 Cr)
May–Sep 2026Sale of Juhu flat to promoter directorAsset monetizationINR 4.776 CrApproved at AGM 25 Sep 2026; completion not confirmed
Jun 2026University of Melbourne research agreement (via Aimco International FZE)R&DAUD 191,096.40 incl. GSTSigned 19 Jun 2026
2025–2026Plant growth regulators / bio-stimulants entryProduct adjacencyNot quantifiedNo launches disclosed

Sustainability/ESG commitments: none quantified. Cost programs with targets: none publicly announced.

Medium-term financial targets / guidance

The only quantified guidance located is the FY2026 revenue target of INR 225 Cr (June 2025), which was missed by 32%. No FY2027 guidance, margin targets or medium-term plan has been disclosed in sources reviewed. Investor conference calls appear to have lapsed after June 2025 (Screener lists no calls after Jun 2025).

Products & Services

Technical-grade active ingredients (manufactured)

ProductClassDescription / capabilityTarget customerLaunch yearPricing modelSource
Chlorpyrifos technical (ethyl and methyl)Organophosphate insecticideFlagship legacy molecule; company claims early-mover status in India after DowExport formulators (Australia, USA, others) and domestic formulatorsNot disclosed (pre-2001)Bulk, spot/contract pricing; not disclosedInvestor presentations FY21; MarketScreener profile
Triclopyr technicalPyridine-class herbicide (woody/broadleaf weed control)Second flagship; supplied to export marketsExport registrants (notably Australia/USA)2,001—Q3FY21 presentation
Bifenthrin technicalPyrethroid insecticideAdded to diversify technical portfolioExport and domestic2,017—Q3FY21 presentation
ImidaclopridNeonicotinoid insecticideProduction started and launched in India in FY2002-03; current status not confirmedDomesticFY2003—IIFL summary
DDVP (dichlorvos)Organophosphate insecticide/fumigantPlant can switch to DDVP with minor modifications; branded "AIMCO-DDVP" referenced in FY23 presentationDomestic——IIFL; Q4FY23 presentation
GlyphosateHerbicidePlant flexibility cited; current production not confirmed———IIFL
Three new molecules (FY2025)—Started in FY2025; two stabilized with production efficiencies by Jun 2025; selected because Chinese players do not supply them at scaleExport and own-brand formulationsFY2025—CARE (Jun 2024, Oct 2025); Q4 FY25 call
Other technicals (to total ~11)Insecticides, fungicides, herbicidesCompany reports "about a dozen" / 11 technicals—Various—Q4FY25 presentation; CARE Jul 2023
Hydroquinone (historical)Non-agro photographic chemical130 tpa plantIndustrialHistorical—IIFL summary

Installed capacity across the plant: 18,500 MT per annum (CARE, Oct 2025 / Jun 2026). Molecule-wise capacity and utilization are not publicly disclosed.

Formulations

CategoryScopeSource
Formulations manufactured90+ formulations: insecticides, fungicides, herbicides, combinations, rodenticides and fumigantsCARE Jul 2023; MarketScreener
Branded SKUs300+ branded SKUsCARE Jul 2023
B2B (bulk) formulationsSupplied to other companies in India and exported (formulation export business)Aug 2020 conference call

Named branded formulations (domestic)

BrandDisclosed inNotes
Aimco ASTRAStockopedia profile (S&P data)—
AIMFIREStockopedia profile—
AIMCOSTAR FSStockopedia profile"FS" denotes a flowable seed-treatment formulation type
Aimco TEJAStockopedia profile—
Aimco ALTROZStockopedia profile—
Aimco WEED NASHAKStockopedia profileHerbicide (name means "weed destroyer")
AIMCO BARRIERStockopedia profile—
Aimco JUMPERStockopedia profile—
AIMPYRADStockopedia profile—
AIMCO MIXStockopedia profile—
Aimco AceStockopedia profile—
BYKILLStockopedia profile—
ANACONDAQ4FY25 earnings presentation—
PYRIBANQ4FY25 earnings presentation—
AIMCO-DDVPQ4FY23 earnings presentationDichlorvos-based

Active ingredients, launch years and pricing for individual brands are not disclosed in sources reviewed; the list below reproduces brand names as published.

Stockopedia's profile cites a portfolio of "approximately 11 molecules" behind the branded range.

Pipeline / adjacent categories

The company has stated an intention to launch Plant Growth Regulators (PGR), bio-nutrients and bio-stimulants (Annual Report FY2025 and CARE, as summarized by Screener). In June 2026 it funded a student research project at the University of Melbourne on "novel products for agriculture" (AUD 191,096.40 including GST, via Aimco International FZE). No launch dates or revenue targets for these categories are disclosed.

Services

No service, licensing or subscription offerings are disclosed. Contract manufacturing (toll/custom supply of an existing technical) was undertaken FY2022–FY2024.

Financial Narrative

All tables: consolidated, INR Cr unless stated; source S&P Global Market Intelligence via StockAnalysis.com (updated 12 Aug 2026), cross-checked with Screener.in (C-MOTS) and CARE Ratings. FY2026 figures are audited (board approval 28 May 2026).

Income statement

Notes: (a) Screener reports FY2025 EPS of INR -7.40 versus S&P's INR -7.55, reflecting weighted-share differences after the March 2025 allotment. (b) S&P revised FY2026 gross profit from INR 32.1 Cr (earlier snapshot) to INR 30.3 Cr after reclassification; latest used. (c) CARE's standalone FY2026 PBILDT is INR -10.33 Cr versus consolidated EBITDA of INR -7.7 Cr here — the gap reflects FX losses (INR 4.6 Cr) being classified differently.

Margins and growth

Revenue CAGR: FY2022→FY2026 (4 years) = -16.2%; FY2021 (INR 176 Cr, Screener)→FY2026 (5 years) = -2.6% (Screener reports 5-year sales CAGR of -2% / -2.48%).

Quarterly trajectory (most recent five quarters)

Source: Screener.in consolidated quarterly results. Discrepancies: Q1FY27 sales are INR 21.97 Cr per Screener but INR 21.79 Cr per Capital Market/Business Standard (13 Aug 2026), which reports a 54.59% YoY decline; a ScanX summary cites Q1FY27 net profit of INR 65.94 lakh (likely standalone) versus consolidated INR 0.61 Cr. Standalone Q2FY26 and Q3FY26 losses were reported as INR 3.56 Cr and INR 2.51 Cr respectively; standalone Q4FY26 loss was INR 3.96 Cr on standalone revenue of INR 30.24 Cr.

Balance sheet

Notes: Retained earnings turned negative (INR -7.6 Cr) at 31 Mar 2026. Zerodha/Tijori reports net debt of INR 12.68 Cr at Mar-2026, consistent with the above. CARE reports overall gearing of 0.58x / 0.70x / 0.89x for FY2024–FY2026.

Ratio analysis

Net debt / EBITDA: FY2022 net cash; FY2023 3.6x; FY2024–FY2026 not meaningful (negative EBITDA). ROE, ROA, ROIC, current ratio, D/E, coverage and turnover are analyst calculations from the S&P data above.

Commentary on trends, inflections and drivers

Revenue. FY2022's 75.6% growth to a record INR 312 Cr coincided with the first year of the three-year contract-manufacturing agreement signed in March 2021 (expected INR 225–250 Cr over three years, i.e., roughly INR 75–85 Cr per year) and with a strong global generic-agrochemical pricing cycle. The 33.9% collapse in FY2023 reflects the global destocking and Chinese price war that CARE explicitly cited (lower stock liquidation, inventory build-up, higher sales returns and weak export demand — CARE, Jul 2023). FY2024 was flat; the contract term ended in March 2024 (analyst inference from the original tenure — renewal not disclosed). FY2025 fell 4.4% despite management's claim of branded growth, and FY2026's 22.2% decline — against a management target of INR 225 Cr (9 Jun 2025 call) — was a 32% miss. The decline accelerated through FY2026: quarterly sales fell from INR 48.3 Cr (Q1) to INR 30.6 Cr (Q4) and INR 22.0 Cr in Q1FY27, a 55% YoY drop.

Gross margin. Gross margin has been volatile within a 16–22% band, troughing at 15.9% in FY2024 when high-cost inventory was liquidated into falling prices, and recovering to 22.0% in FY2025 as the branded mix improved. The FY2026 dip to 19.6% and the Q1FY27 rebound (TTM gross margin 25.3%; Q1FY27 OPM 8.2%) suggest the company is deliberately shrinking low-margin technical/B2B volumes — consistent with higher margin on far lower revenue.

Operating leverage. Fixed costs (SG&A + other opex ≈ INR 38 Cr in FY2026) now exceed gross profit (INR 30.3 Cr), so EBITDA is structurally negative at current scale. A rough breakeven at a 20% gross margin requires revenue of ~INR 190 Cr; at 25%, ~INR 150 Cr (analyst estimate, assuming fixed costs hold flat).

Below-the-line. FX losses rose to INR 4.6 Cr in FY2026 (from INR 1.2 Cr), a significant item for a company of this size, likely reflecting import payables in foreign currency. Interest expense fell in FY2026 as debt was repaid. Tax credits (INR 3.6 Cr) cushioned losses, but the corresponding deferred-tax asset has grown to INR 9.6 Cr — 54% of equity — whose recoverability depends on a return to taxable profits.

Balance sheet and liquidity. Equity has shrunk by 65% in four years (INR 50.5 Cr → INR 17.7 Cr). The company moved from net cash (FY2022) to persistent net debt of INR 12–16 Cr. Working capital turned sharply negative (INR -20.2 Cr) because payables (259 days) far exceed receivables and inventory days — CARE notes the low operating cycle results from late payments to creditors, with suppliers granting 90–120 days' clean credit. FY2026 operating cash flow (INR 5.7 Cr) was generated almost entirely by working-capital release (receivables down INR 23 Cr, inventory down INR 19 Cr, partly offset by payables paydown of INR 27 Cr), not by earnings. Cash fell to INR 2.6 Cr. Bank lines are heavily utilized (cash credit ~96%, EPC/PCFC ~72% over the 12 months to Aug 2024 — CARE). The attempt to sell a Mumbai flat for INR 4.78 Cr to "support immediate working capital and cash flow requirements" (postal-ballot notice, Jun 2026) underscores liquidity strain.

Capital allocation. Capex has been cut to maintenance levels (INR 1.2–1.9 Cr in FY2025–FY2026 versus INR 6.7–7.8 Cr in FY2022–FY2023). Dividends were suspended after FY2023. The only equity raise was INR 2.02 Cr (March 2025).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRelationshipJurisdictionRole (as disclosed)Source

Aimco Pesticides Ltd

Parent / listed entity

India

Manufacturing, domestic and export sales

Filings

Aimco International FZE

Wholly owned subsidiary

UAE (Dubai)

International sales/trading office; counterparty to University of Melbourne research agreement (Jun 2026)

BSE (Dec 2024, Jun 2026)

Aimco KREPL Australia Pty Ltd

Wholly owned subsidiary (incorporated 7 May 2024; capitalized AUD 10,000 Dec 2024 + AUD 30,000 Jun 2025)

Australia

Market access / registration vehicle for Australia (inferred from purpose of investment; detailed business not disclosed)

BSE (Dec 2024, Jun 2025)

Aimco Ecoscience Ltd

Wholly owned subsidiary

India

Not disclosed in detail (name suggests bio/eco-products; further INR 5 lakh invested Dec 2024/Jan 2025)

BSE

Aimco KR Agro Pvt Ltd

—

India

—

ICICI Direct profile

AIMCO KR Agro LLP

—

India

—

ICICI Direct profile

“—” = not publicly disclosed.

Results by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Segment revenue = revenue from operations (INR Cr)

207.2197.7153.9

YoY growth (%)

0.4-4.6-22.2

Contribution to total revenue (%)

100100100

Operating income / EBIT (INR Cr)

-11.4-6.1-11.0

Pre-tax income (INR Cr)

-13.3-9.6-15.8

EBIT margin (%)

-5.5-3.1-7.1

Pre-tax margin (%)

-6.4-4.8-10.2

Business line share of revenue (%)

Business line share of revenue (%)FY2022FY2023FY2024

Technical grade chemicals

—5951

Branded formulations (domestic B2C)

2229—

B2B formulations

—9—

Domestic formulations (branded + B2B) share of total income

——49

Export share of revenue

—50—

Implied revenue (INR Cr)

Implied revenue (INR Cr)FY2022FY2023FY2024

Technical grade chemicals

—121.7105.7

Branded formulations

68.659.8—

B2B formulations

—18.6—

Income Statement and Per-Share Data

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Revenue from operations

312.0206.2207.2197.7153.9

Other operating revenue

0.70.50.20.60.3

Cost of revenue

248.2161.4174.4154.6123.9

Gross profit

64.545.333.043.630.3

SG&A

10.715.018.718.816.7

Other operating expenses

34.927.021.526.821.2

EBITDA

18.33.3-7.3-2.1-7.7

Depreciation & amortization

2.23.64.13.93.3

Operating income (EBIT)

16.2-0.2-11.4-6.1-11.0

Interest expense

1.52.42.63.01.4

FX gain/(loss)

-0.3-0.8-0.4-1.2-4.6

Pre-tax income

14.5-2.8-13.3-9.6-15.8

Income tax (negative = credit)

3.9-0.6-3.3-2.3-3.6

Net income

10.7-2.2-10.0-7.2-12.2

EPS basic (INR)

11.12-2.28-10.48-7.55-12.47

EPS diluted (INR)

11.12-2.28-10.48-7.55-12.47

Dividend per share (INR)

2.01.0000

Margin Analysis (%)

Metric (%)FY2022FY2023FY2024FY2025FY2026

Revenue growth (total revenue)

75.6-33.90.4-4.4-22.2

Gross margin

20.621.915.922.019.6

EBITDA margin

5.91.6-3.5-1.1-5.0

Operating (EBIT) margin

5.2-0.1-5.5-3.1-7.1

Net margin

3.4-1.1-4.8-3.7-7.9

Effective tax rate

26.621.924.624.522.7

Income Statement and Margin Analysis (%)

Metric (INR Cr)Q1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Sales

48.3245.6030.3830.6421.97

Operating profit

-1.15-3.42-2.15-4.411.79

OPM (%)

-2.38-7.50-7.08-14.398.15

Interest

0.510.490.430.380.27

Depreciation

0.810.890.860.850.85

Profit before tax

-2.37-4.77-3.30-5.350.87

Net profit

-1.50-4.02-2.53-4.160.61

EPS (INR)

-1.53-4.11-2.59-4.250.62

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Balance Sheet and Per-Share Data

Metric (INR Cr, at 31 March)FY2022FY2023FY2024FY2025FY2026

Total assets

167.0145.6149.6176.0129.6

Cash & short-term investments

8.11.73.75.52.6

Trade & other receivables

41.226.351.154.830.0

Inventory

77.877.652.372.954.1

Total current assets

136.9111.0109.4136.789.1

Property, plant & equipment

22.926.326.226.123.4

Goodwill & intangibles

6.45.85.34.85.2

Deferred tax assets

00.33.76.09.6

Trade payables

109.076.283.7114.987.3

Short-term debt incl. current portion of LTD

012.616.619.514.5

Long-term debt

0.010.011.80.20.05

Total debt incl. leases

0.113.719.420.415.0

Net debt (negative = net cash)

-8.012.015.714.912.4

Total current liabilities

114.296.3109.5142.6109.3

Shareholders' equity

50.546.335.029.917.7

Working capital (current assets – current liabilities)

22.814.7-0.1-5.9-20.2

Book value per share (INR)

52.6948.3036.5530.5518.06

Cash Flow

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Operating cash flow

22.6-10.17.42.75.7

of which change in working capital

7.1-11.514.03.416.7

Capital expenditure

-7.8-6.7-5.4-1.2-1.9

Free cash flow

14.8-16.82.01.53.8

Dividends paid

-0.9-2.1-1.000

Share buybacks

00000

Equity issued

0002.00

Net debt issued/(repaid)

-11.012.45.11.0-5.4

Cash interest paid

1.50.92.63.11.9

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE (%, on average equity)

23.4-4.5-24.7-22.3-51.3

ROA (%, on average assets)

7.1-1.4-6.8-4.4-8.0

ROCE (%, Screener)

31-1-18-12-34

Pre-tax ROIC (%, EBIT / year-end invested capital)

38.1-0.3-22.5-13.6-36.5

Current ratio (x)

1.201.151.000.960.82

Debt / equity (x)

0.000.300.550.680.85

Interest coverage (EBIT / interest, x)

11.0-0.1-4.3-2.0-7.7

Asset turnover (x, revenue / average assets)

2.081.321.401.211.01

Debtor days (Screener)

4843829363

Inventory days (Screener)

115177110174161

Payable days (Screener)

161174177274259

Cash conversion cycle (days, Screener)

24715-8-35

Revenue by Region (%)

Geographic metricFY2021FY2023FY2024

Export share of revenue (%)

—50—

Domestic formulations share of total income (%)

——49

Number of export countries (approx.)

4245—

Business Lines

Business linePrimary geographiesEvidence

Technicals

Exports — primarily Australia and USA; also Malaysia, Brazil, Africa, Gulf

Investor presentations FY21–FY23; CARE Sep 2023

B2B formulations

Export formulation business and domestic bulk

Aug 2020 call

Branded formulations

India — West Bengal, Gujarat, Odisha, Andhra Pradesh, Tamil Nadu, Madhya Pradesh, Maharashtra

Q4FY25 presentation

Share Price & Returns

HorizonReturnSource

1-year

-41% to -45% (various dates Sep–Oct 2026)

ScanX; Screener

3-year

-29% CAGR (≈ -64% cumulative)

Screener

5-year

-16% CAGR; ≈ -59% cumulative

Screener; ScanX

10-year

-3% CAGR

Screener

Share Count (million) and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Shares outstanding (million)

9.589.589.589.789.78

Book value per share (INR)

52.6948.3036.5530.5518.06

EPS (INR)

11.12-2.28-10.48-7.55-12.47

Dividend per share (INR)

2.01.0000

Free cash flow per share (INR)

15.43-17.492.111.563.85

Valuation Multiples

MultipleAimcoComment

Market cap (INR Cr)

41.1

9.78 million shares

Enterprise value (INR Cr)

53.5

Market cap + total debt INR 15.0 Cr – cash INR 2.6 Cr (31 Mar 2026)

EV/Sales (FY2026)

0.35x

Revenue INR 153.9 Cr

EV/Sales (TTM)

0.42x

TTM revenue INR 128.6 Cr

P/B

2.33x

BVPS INR 18.06

P/Tangible book

3.29x

TBVPS INR 12.77

Dividend History

Fiscal yearDividend per share (INR)Payout ratio (%)Source

FY2018

—19

Screener

FY2019

—19

Screener

FY2020

—22

Screener

FY2021

—46

Screener

FY2022

2.018

S&P; Screener

FY2023

1.0 (ex-date 18 Sep 2023, paid despite loss)

—

S&P; MarketsMOJO

FY2024–FY2026

00

S&P; Motilal Oswal (FY2026 nil)

Agency by Date

DateAgencyLong-termShort-termActionSource

6 Oct 2022

CARE

BBB-; Stable

A3

Assigned/reaffirmed

CARE rating history

20 Jul 2023

CARE

BB+; Stable

A4+

Downgrade

CARE

29 Sep 2023

CARE

BB+; Stable

A4+

Reaffirmed

CARE

6 Jun 2024

CARE

BB; Stable

A4

Downgrade

CARE

3 Oct 2024

CARE

BB; Stable

A4

Reaffirmed

CARE

6 Oct 2025

CARE

BB-; Stable (INC)

A4 (INC)

Downgrade; Issuer Not Cooperating

CARE

8 Jun 2026

CARE

B-; Stable (INC)

A4 (INC)

Downgrade

CARE

Debt Facilities

FacilityAmount (INR Cr)MaturityRating

Fund-based / non-fund-based LT/ST

16.00

Revolving

B- / A4 (INC)

Fund-based / non-fund-based LT/ST

5.00

Revolving

B- / A4 (INC)

Forward contract (non-fund-based ST)

1.00

Revolving

A4 (INC)

Term loan (long term)

3.00

31 Mar 2027

B- (INC)

Total rated facilities

25.00

——

Analyst Conclusions

Management guidance

No formal FY2027 guidance has been issued. The last quantified target (FY2026 revenue INR 225 Cr, June 2025) was missed by 32%. Management's strategic direction emphasizes branded formulations, new molecules, bio-inputs and the Australian subsidiary.

Consensus expectations

None — the stock has no analyst coverage.

Bull case

  1. Margin inflection on a cleaned-up mix. Q1FY27 delivered an 8.2% operating margin and a net profit on revenue of only ~INR 22 Cr, and TTM gross margin reached 25.3%, suggesting that exiting low-margin technical/B2B volume has reset unit economics; restoring revenue to FY2025 levels (~INR 198 Cr) at a 25% gross margin would imply positive EBITDA of roughly INR 10 Cr.

  2. Balance-sheet repair underway. Net debt fell from INR 15.7 Cr (FY2024) to INR 12.4 Cr (FY2026), FY2026 FCF was positive (INR 3.8 Cr), and the approved INR 4.78 Cr property sale could cut net debt by about a third.

  3. Option value at a trough valuation. At ~0.4x EV/Sales and a market cap of ~INR 41 Cr, the market prices in continued decline; new molecules, branded growth and any rebound in generic export pricing (as industry destocking ends) offer asymmetric upside, with promoters holding 54.45% and no pledges.

Bear case

  1. Revenue collapse is not just mix. Revenue fell 22% in FY2026 and ~55% YoY in Q1FY27 while peers such as Rallis (+9%) grew, indicating loss of competitiveness and working-capital-constrained selling rather than a deliberate pruning alone.

  2. Solvency and liquidity risk. Equity of INR 17.7 Cr supports payables of INR 87.3 Cr and short-term debt of INR 14.5 Cr; current ratio is 0.82x and cash only INR 2.6 Cr. CARE's B- rating and non-cooperation could tighten bank and supplier credit, and a further year of losses at the FY2026 rate would nearly wipe out remaining equity.

  3. Governance and disclosure discount. Rating-agency non-cooperation, discontinued investor calls, a related-party asset sale rejected by minorities then pushed through at the AGM, and family concentration across MD/CFO/board roles warrant a structural discount and raise the risk of value leakage.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhat to watch
Q2 FY27 results~Mid-Nov 2026Whether Q1 profitability holds through the kharif-season quarter; revenue trajectory
Completion of Juhu flat saleH2 FY2027Receipt of INR 4.78 Cr and use of proceeds
Term-loan maturity31 Mar 2027Repayment / refinancing of INR 3 Cr term loan
CARE rating actionsOngoingFurther downgrade or withdrawal; any return to cooperation
Working-capital metricsQuarterlyPayable days (259 at FY2026), bank-line utilization, cash
Rabi season (Oct 2026 – Mar 2027)Q3–Q4 FY27Branded formulation sell-through
New molecules / bio-inputsFY2027Disclosure of revenue contribution or launches
Australian subsidiaryFY2027First revenue disclosures or registrations
Export pricing for genericsOngoingChinese pricing for chlorpyrifos/bifenthrin/triclopyr
Deferred-tax assetFY2027 auditAny impairment of INR 9.6 Cr DTA
Investor communicationOngoingResumption of earnings calls/presentations

Concluding analyst verdict

Aimco Pesticides is a distressed micro-cap whose investment case now rests on survival rather than growth. The company that delivered INR 312 Cr of revenue and INR 10.7 Cr of profit in FY2022 has since lost half its revenue, four consecutive years of earnings, and two-thirds of its equity. FY2026 was the low point on the annual numbers — revenue down 22% to INR 153.9 Cr, EBITDA of INR -7.7 Cr and a net loss of INR 12.2 Cr — and Q1FY27's return to a small profit came on revenue that more than halved. That combination suggests a business deliberately shrinking toward its higher-margin core, but also one that may be constrained by liquidity from selling more.

The balance sheet is the binding constraint. With INR 17.7 Cr of equity, INR 2.6 Cr of cash, a current ratio below 1x and suppliers effectively financing operations, Aimco has little room for another loss-making year. CARE's slide from BBB- to B- in under four years, compounded by the company's non-cooperation, is a material warning, as is the need to sell a residential flat to a promoter director to fund working capital.

There are genuine assets — a flexible 18,500 MTPA plant, decades of process know-how, export registrations, a branded franchise and new molecules — and the shares trade at roughly 0.4x EV/Sales. But the governance profile (family-concentrated management, related-party dealings, sparse disclosure) and the structural decline of the legacy chlorpyrifos franchise argue for caution.

Verdict: High-risk, speculative. The stock is investable only for special-situation investors willing to underwrite a turnaround on the evidence of sustained quarterly profitability, completion of the asset sale, stabilizing revenue above ~INR 40 Cr per quarter, and restored transparency with lenders and rating agencies. Until at least two of these are visible, the downside risks — equity erosion, credit tightening and minority value leakage — outweigh the option value embedded in the depressed valuation.


DATA NOTES & SOURCES

The FY2025-26 annual report and recent earnings-call/presentation PDFs on bseindia.com could not be retrieved directly; data from them is used only where quoted in search snippets or third-party summaries.

Primary sources consulted:

  • S&P Global Market Intelligence data via StockAnalysis.com — income statement, balance sheet, cash flow (BOM:524288), updated 12 Aug 2026

  • Screener.in — consolidated quarterly/annual results, ratios, shareholding, document index (accessed Oct 2026)

  • CARE Ratings press releases on Aimco Pesticides — 20 Jul 2023, 29 Sep 2023, 6 Jun 2024, 6 Oct 2025, 8 Jun 2026

  • BSE filings: Outcome of board meeting (23 Dec 2024); Q4FY25 earnings presentation (2 Jun 2025); Q4 FY25 earnings call transcript (9 Jun 2025); investor presentations Jul 2020, Sep 2020, Feb 2021, Jun 2021, May 2023; Aug 2020 call transcript

  • ScanX (Dhan) summaries of BSE disclosures: FY2026 results (29 May 2026), postal ballot notice (23 Jun 2026), scrutinizer report (25 Jul 2026), University of Melbourne agreement (19 Jun 2026), director appointment/death disclosures (Sep 2025), AGM outcome (25 Sep 2026)

  • Business Standard / Capital Market — Q1 FY27 results (13 Aug 2026)

  • Whalesbook — Q4 FY26 standalone/consolidated results (28 May 2026)

  • Investywise — 39th AGM schedule (12 Aug 2026)

  • AgroPages — contract-manufacturing agreement (Mar 2021)

  • SEBI open-offer documents (2005–2006)

  • Company website (aimcopesticides.com) management pages; MarketScreener, Stockopedia, Simply Wall St, Pocketful, Business Standard, MarketsMOJO, Bajaj Finserv, Trendlyne, ICICI Direct, IIFL, Aditya Birla Capital, Sharekhan, Fyers, Zerodha, Kotak Securities broker profiles

  • Peer data: Rallis India FY2026 press release (27 Apr 2026) and Arihant/Multibagg summaries; Dhanuka Agritech FY2026 press release (19 May 2026) and Multibagg/AskFuzz summaries; India Pesticides Q1 FY27 summary (AskFuzz)

  • Industry data: Rubix Data Sciences (Jun 2025); Mordor Intelligence; P&S Intelligence; Nexdigm

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenure on boardBackground / educationAge (disclosed, varies by source)Source

Mayoor (Mayur) Amin

Chairman, Independent Non-Executive Director

Chairman since 12 Feb 2025; earlier listed as non-independent/independent director

——

IndMoney; Pocketful; Stockopedia

Dr. Samir Pradeep Dave

Managing Director (Executive, promoter)

Director since May 1995; MD since 13–14 Feb 2024; re-appointed MD at 39th AGM (25 Sep 2026)

PhD in synthetic organic chemistry (University of Bombay), trained under Dr. A. V. Rama Rao; 20+ years in pesticide process R&D; heads R&D and production; founder director of AgroCare (global generic agrochemical association, Belgium); director, Agriculture Skill Council of India

54–59

Company website; MarketScreener; Simply Wall St

Pradeep Pushkarrai Dave

Founder; Executive Whole-Time Director (some sources list as non-executive)

Since incorporation (1987)

Chemistry graduate (University of Mumbai); 40+ years in pesticides; President of PMFAI (since 2010); governing body member, Institute of Pesticide Formulation Technology; Chemtech Foundation board; former Chairman, Society of Chemical Industry (India)

78–83

Company website; MarketScreener; CARE

Ashit Pradeep Dave

Whole-Time Director & CFO

Since 19 Aug 1996

Commerce graduate; MEP from IIM Ahmedabad; finance, legal and commercial lead

50–54

MarketScreener; company team page

Tarlika Pradeep Dave

Non-Executive Director (promoter)

Since 15 Sep 2025 (5-year term to 14 Sep 2030)

~30 years in pesticide industry; led Amisco Agro-Chem Ltd (principal promoter vehicle); wife of Pradeep Dave, mother of Samir and Ashit Dave

80–81

ScanX (BSE disclosure)

Ashok Kundanmal Jain

Independent Non-Executive Director

———

Pocketful

Jagat Harish Shah

Independent Non-Executive Director

———

Pocketful

Jignesh Anantrai Nagodra

Independent Non-Executive Director

———

Pocketful

Reema Manoj Vara

Company Secretary & Compliance Officer

———

Pocketful; BSE filings

“—” = not publicly disclosed.

Directors' Remuneration

ExecutiveSalary (INR Cr)BonusStock awardsTotal (INR Cr)Fiscal yearSource

Dr. Samir Dave (MD)

1.20001.20

FY2024

S&P data via Simply Wall St

Ashit Dave (WTD & CFO)

1.20001.20

FY2024

S&P data via Simply Wall St

Independent Chairman (sitting fees)

———0.009

FY2024

Simply Wall St

Major Shareholders

HolderSharesStake (%)CategorySource / date

Amisco Agro-Chem Ltd

28,87,925

29.52

Promoter group

Bajaj Finserv / MarketsMOJO (Mar–Jun 2026)

Pradeep Pushkarrai Dave

9,02,091

9.22

Promoter

Bajaj Finserv

Ashit Pradip Dave

4,82,077

4.93

Promoter

Bajaj Finserv

Samir Pradeepbhai Dave

4,04,018

4.13

Promoter

Bajaj Finserv

Damodar Prasad Agarwal

—3.57

Public (largest non-promoter)

MarketsMOJO (Mar 2026)

Priyal Dave

1,50,500

1.54

Promoter group

Bajaj Finserv

Shail Samir Dave

1,50,100

1.53

Promoter group

Bajaj Finserv

Shreya Ashit Dave

92,7870.95

Promoter group

Bajaj Finserv

Nandini Ashit Dave

92,2870.94

Promoter group

Bajaj Finserv

Diya Ashit Dave

92,2870.94

Promoter group

Bajaj Finserv

Meghna Samir Dave

56,0000.57

Promoter group

Bajaj Finserv

Late Elizabeth Shrivastava (estate)

16,5860.17

Promoter group (ceasing per SEBI rules)

Bajaj Finserv

“—” = not publicly disclosed.

Shareholding Pattern

Category (%)Jun2025Sep2025Dec2025Mar2026Jun2026

Promoters

54.4554.4554.4554.4554.45

FIIs

0.040.040.000.000.00

DIIs

0.030.030.000.000.00

Public

45.4745.4845.5545.5545.55

Number of shareholders

11,39811,3547,9877,9027,792

Competitive Landscape

Competitors by Segment

Business lineNamed competitorsNature of competition

Export technicals (chlorpyrifos, triclopyr, bifenthrin, other generics)

Chinese generic producers (as a class, cited by CARE as the main pressure); Indian technical producers: UPL, Gharda Chemicals (unlisted), Meghmani Organics, Bharat Rasayan, India Pesticides, Heranba Industries, Punjab Chemicals & Crop Protection, Bhagiradha Chemicals & Industries, Shivalik Rasayan; originator Corteva (Dow legacy) in triclopyr/chlorpyrifos

Price-driven; scale and backward integration decisive

Domestic branded formulations

Dhanuka Agritech, Rallis India (Tata), UPL (Advanta/domestic), PI Industries (domestic brands), Bayer CropScience India, Sumitomo Chemical India, Insecticides (India), Best Agrolife, GSP Crop Science, Dharmaj Crop Guard, NACL Industries, Crystal Crop Protection (unlisted)

Distribution reach, brand pull, credit terms to dealers

Global generic formulation/registration players

Sharda Cropchem (registration-led exporter), Nova Agritech

Registration portfolios in export markets

Small-cap peers (similar scale)

Super Crop Safe, Bhaskar Agrochem, Phyto Chem (India)

Similar sub-scale generics

Peer Comparison FY2026

MetricAimco PesticidesRallis IndiaDhanuka AgritechIndia Pesticides

Revenue from operations (INR Cr)

153.92,8972,019.8—

Revenue growth FY2026 (%)

-22.28.8-0.8

Q1FY27 standalone -8.6 YoY

EBITDA (INR Cr)

-7.7362——

EBITDA margin (%)

-5.012.5—

Q1FY27 OPM 14.1

Net profit (INR Cr)

-12.2184287.2

Q1FY27 PAT 22.7

Net margin (%)

-7.96.414.2—

Balance sheet

Net debt INR 12.4 Cr; equity INR 17.7 Cr

Cash & liquid INR 541 Cr

Buyback INR 70 Cr announced

Debt-free, net cash

Peer Comparison FY2026 by Company

CompanyMarket cap (INR Cr)P/E (x)Annual PAT (INR Cr)

PI Industries

36,26131.11,321

Sumitomo Chemical India

24,89243.0543

Bayer CropScience India

17,77724.3689

Sharda Cropchem

6,97111.1681

Rallis India

4,08219.1184

Shivalik Rasayan

49436.118

Nova Agritech

21816.913

Aimco Pesticides

46—-12

Company Snapshot

$17.8M

Revenue

1987

Founded

District Ratnagiri, India

Headquarters

SWOT Analysis

Strengths

  • Installed capacity and flexibility: single plant with 18,500 MTPA installed capacity able to switch across molecules (CARE, Jun 2026; IIFL company summary).
  • Legacy technical know-how: early commercialization of chlorpyrifos and triclopyr technical in India (triclopyr in 2001) and bifenthrin in 2017 (Q3FY21 presentation).
  • Broad portfolio: ~11 technicals, 90+ formulations and 300+ branded SKUs (CARE, Jul 2023).
  • Export franchise: historically ~50% of revenue exported to ~42–45 countries including Australia and the USA (CARE, Sep 2023).
  • Promoter industry depth: founder has 40+ years' experience and leads PMFAI; MD is a PhD process chemist (CARE; company website).
  • Improving unit economics on smaller base: TTM gross margin 25.3% and Q1FY27 OPM 8.2% with a return to quarterly profit (S&P; Screener).

Weaknesses

  • Sustained losses: net losses in FY2023–FY2026 totalling INR 31.6 Cr; FY2026 loss INR 12.2 Cr (S&P).
  • Eroded equity: net worth down from INR 50.5 Cr (FY2022) to INR 17.7 Cr (FY2026); retained earnings negative (S&P).
  • Stretched liquidity: current ratio 0.82x; cash INR 2.6 Cr; cash-credit utilization ~96% (CARE; S&P).
  • Supplier-funded balance sheet: payable days of 259 (FY2026) versus 161 (FY2022) (Screener).
  • Customer concentration: top-10 customers >50% of FY2024 revenue (CARE).
  • Disclosure and governance weaknesses: CARE "Issuer Not Cooperating" since Oct 2025; investor calls appear discontinued after Jun 2025; family-dominated executive team (CARE; Screener).

Opportunities

  • Branded formulation mix shift: branded share rose from 22% to 29% (FY2022–FY2023) and grew in FY2025 (CARE; Q4FY25 call).
  • New molecules: three launched in FY2025 in segments with limited Chinese supply (CARE).
  • Herbicide demand: Indian herbicide exports grew ~20% CAGR FY2020–FY2025 (Rubix) — relevant to triclopyr and weed products.
  • Biologicals/PGRs: stated entry into PGRs, bio-nutrients and bio-stimulants (Annual Report FY2025 summary).
  • Australian presence: subsidiary set up and University of Melbourne research agreement (BSE, 2024–2026).
  • Asset monetization: INR 4.78 Cr flat sale approved at AGM provides near-term liquidity equivalent to ~27% of equity (AGM outcome, Sep 2026).

Threats

  • Chinese competition: cited by CARE as the primary profitability drag (Oct 2025).
  • Chlorpyrifos regulation: restrictions in EU/US and the 2025 Stockholm Convention listing shrink addressable markets (public regulatory record).
  • Credit downgrade spiral: CARE BBB- (Oct 2022) to B- (Jun 2026) may tighten bank lines and supplier credit (CARE rating history).
  • Supplier-credit withdrawal: with payables at INR 87.3 Cr versus equity of INR 17.7 Cr, any tightening of the 90–120-day clean credit would trigger a liquidity squeeze (CARE; S&P).
  • Monsoon/seasonality: below-normal monsoon outlook flagged by peers for 2026 (Dhanuka Q4FY26 commentary).
  • Deferred-tax asset impairment: INR 9.6 Cr DTA (54% of equity) at risk if losses persist (S&P).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
29 May 2025Board approves audited FY2025 results: consolidated revenue INR 197.7 Cr, net loss INR 7.24 Cr; Q4 FY25 loss INR 5.15 CrThird consecutive annual loss
2 Jun 2025Q4FY25 earnings presentation filed (business segments, brands Anaconda/Pyriban, state presence)Last investor presentation located
9 Jun 2025Q4 FY25 earnings call: FY2025 described as challenging; brand business grew; 3 new molecules (2 stabilized); FY2026 revenue target INR 225 CrGuidance later missed by 32%
11–13 Jun 2025Further AUD 30,000 investment in Aimco KREPL Australia; stock rose on the newsAustralian build-out
25 Jun 2025Trading window closed from 1 Jul 2025Routine
10 Jul 2025Regulation 74(5) depository compliance certificate (Q1)Routine
14 Aug 2025Q1 FY26 results: sales INR 48.3 Cr, net loss INR 1.50 Cr; AGM schedulingWeak start to FY2026
4 Sep 2025Death of promoter and Whole-Time Director Elizabeth C. ShrivastavaLoss of long-serving international-markets executive; she ceases to be in promoter group
15 Sep 2025Tarlika P. Dave appointed Non-Executive Additional Director (5-year term)Restores woman director; deepens family board representation
Sep 202538th AGM held (exact date not confirmed in sources)Routine
6 Oct 2025CARE downgrades to BB-; Stable / A4 and moves to Issuer Not Cooperating after company failed to provide informationCredit deterioration; governance/disclosure red flag
18 Oct 2025Shareholding pattern for Sep 2025 filed (promoters 54.45%)Routine
14 Nov 2025Q2 FY26 results: sales INR 45.6 Cr; consolidated loss INR 4.02 Cr (standalone INR 3.56 Cr)Losses widen
17 Nov 2025Newspaper publication of Q2 resultsRoutine
29 Jan 2026Board meeting intimation for 12 Feb 2026; trading window closed from 1 Jan 2026Routine
12 Feb 2026Q3 FY26 results: sales INR 30.4 Cr (-40% YoY); consolidated loss INR 2.53 Cr (standalone INR 2.51 Cr)Revenue slump accelerates
13 Feb 2026Regulation 30 disclosure (content not detailed in sources)—
1 Apr 2026Special window (5 Feb 2026 – 4 Feb 2027) opened for re-lodgement of physical share-transfer requests rejected before 1 Apr 2019SEBI-mandated investor-service measure
2 Apr 2026Share price at INR 40.54; P/B 1.62 (ICICI Direct)Near 52-week low
10 Apr 2026Regulation 74(5) certificate for Q4 FY26 (RTA: MUFG Intime)Routine
20 May 2026Board meeting notice for FY2026 resultsRoutine
28 May 2026FY2026 results: revenue INR 153.88 Cr (-22%); consolidated loss INR 12.20 Cr; Q4 loss INR 4.16 Cr; unmodified audit opinion; V. J. Talati & Co. appointed cost auditor for FY2027; board approves RPT sale of Juhu flatWorst loss in the series; asset sale to fund working capital
8 Jun 2026CARE downgrades long-term rating to B-; Stable (INC), citing non-cooperation and three years of operating and net lossesRating now deep sub-investment grade
19 Jun 2026Student Research Project Agreement with University of Melbourne and Aimco International FZE (AUD 191,096.40 incl. GST)Small R&D commitment despite cash strain
23–24 Jun 2026Postal-ballot notice published for sale of Juhu flat to promoter director Tarlika Dave for INR 4.776 CrRelated-party asset disposal
24–25 Jul 2026Scrutinizer: RPT resolution defeated — 62.24% of votes cast against; participation 1.12% (23 members, 1,09,775 shares); promoters (interested) did not voteRare minority rejection of a promoter RPT
12 Aug 2026Q1 FY27 results: consolidated sales ~INR 22 Cr (-55% YoY); net profit INR 0.61 Cr vs loss INR 1.50 Cr; OPM 8.2%; AGM set for 25 Sep 2026, book closure 19–25 Sep, e-voting record date 18 SepFirst quarterly profit since Q3 FY25, on sharply lower revenue
26–27 Aug 2026FY2025-26 Annual Report filed with BSE; AGM notice and newspaper publicationStatutory
24 Sep 2026Trading window closed from 1 Oct 2026 until 48 hours after Q2 FY27 resultsQ2 FY27 results expected ~mid-Nov 2026
25 Sep 202639th AGM (VC/OAVM): FY2026 accounts adopted; Dr. Samir Dave re-appointed MD; cost-auditor remuneration ratified; RPT for property sale approvedRPT approved two months after postal-ballot rejection
16 Oct 2026Shares close at INR 41.99 (+3.1% on day); market cap ≈ INR 41 Cr; 1-year return ≈ -41% to -45%Valuation near multi-year lows

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Revenue from operations fell from INR 3,120 Mn in FY2022 to INR 1,539 Mn in FY2026.
Aimco Pesticides Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations3,1202,0622,0721,9771,539
Other operating revenue75263
Cost of revenue2,4821,6141,7441,5461,239
Gross profit645453330436303

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.